Indaptus Therapeutics is trading 5% up at $1.05 in after-hours trading after closing at $1.00 on August 17, 2026; no major company-specific announcement tied to the increase was identified.
- The latest reported catalyst was the August 13, 2026 quarterly update, which described a strategic pivot after the Decoy20 trial halt and narrower losses; available evidence does not directly link it to the move.
- Broader markets were weaker, so macro sentiment does not clearly explain the gain.